Core Viewpoint - The chairman and general manager of Maiwei Biopharma, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about management stability and internal control effectiveness during a critical period for the company's H-share listing [1][2]. Company Overview - Maiwei Biopharma is an innovative biopharmaceutical company with a full industry chain layout, focusing on the research, production, and sales of innovative drugs and biosimilars, including antibodies, ADC drugs, and recombinant proteins [1]. - The company has launched three products, which are gradually increasing in sales volume, but has not achieved profitability since its establishment in 2017, accumulating losses of nearly 6 billion yuan [1][7]. Financial Performance - The company reported revenues of 27.73 million yuan in 2022, 128 million yuan in 2023, and 200 million yuan in 2024, with year-on-year growth rates of 70.88%, 361.03%, and 56.28% respectively [6]. - However, in the first quarter of 2024, revenue decreased to 45 million yuan, a year-on-year decline of 33.70%, with a net loss of 292 million yuan, down 41.85% year-on-year [6][7]. - Cumulative losses since establishment exceed 6 billion yuan, with net losses of 955 million yuan, 1.05 billion yuan, and 1.04 billion yuan for the years 2022, 2023, and 2024 respectively [7]. Debt and Financing - The company's debt ratio increased from 24.00% in 2022 to 63.61% in 2024, with total liabilities reaching 2.72 billion yuan, a year-on-year increase of 44.53% [8]. - To meet funding needs and enhance internationalization, the company submitted a listing application to the Hong Kong Stock Exchange in January 2024 and is also seeking to issue up to 500 million yuan in targeted debt financing tools [8]. Management and Governance - Liu Datao, the chairman, holds 3.78% of the company's shares and has a background in molecular biology and pharmaceutical chemistry, having co-founded Maiwei Biopharma in 2017 [3][4]. - The actual controllers of the company are Tang Chunshan and Chen Shanna, holding 42.38% of the voting rights [4].